Greg Laub

'We need more inclusive enrollment in the trials that guide approvals,' says Zunairah Shah, MD

Experts discuss biomarker-driven strategies and adaptive trial design

Study from China not ready for prime time

Experts explore prospects for post-neoadjuvant use in early disease as well as metastatic setting

James Lawler, MD, MPH, says a coordinating office for U.S. biodefense strategy is a necessity

Leigh Turner, PhD, explains the evidence gap and how athletes fuel risky markets

'This isn't an issue of willpower or anything else,' says Spencer Nadolsky, DO

Despite approval of tirzepatide in OSA, a lack of protocols slows uptake in sleep medicine

Real-world French study finds broad benefit, solid comfort, high use

Clinical and pathologic features remain essential tools when testing isn't available